Search results
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed...
WDTN-TV 2 Dayton· 1 week ago...continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2 Treatment with...
A Look at Trabectedin Monotherapy for Recurrent Ovarian Cancer
MedPage Today· 1 week agoTreatment with trabectedin monotherapy did not extend median overall survival (OS) in a prospective,...
Peripheral Neuropathy Market is Expected to Hit USD 7.95 Billion by 2031
Digital Journal· 7 days agoAccording to SNS Insider, Peripheral Neuropathy Market is projected to reach USD 7.95 Billion by...